Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
HER2
biomarkers
breast cancer
circulating microRNAs
ct-miR-148a-3p
trastuzumab
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Feb 2020
18 Feb 2020
Historique:
received:
06
09
2019
revised:
11
02
2020
accepted:
13
02
2020
entrez:
23
2
2020
pubmed:
23
2
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Circulating microRNA (ct-miRNAs) are able to identify patients with differential response to HER2-targeted therapy. However, their dynamics are largely unknown. We assessed 752 miRNAs from 52 NeoALTTO patients with plasma pairs prior and two weeks after trastuzumab. Increased levels of ct-miR-148a-3p and ct-miR-374a-5p were significantly associated with pathological complete response (pCR) (
Identifiants
pubmed: 32085669
pii: ijms21041386
doi: 10.3390/ijms21041386
pmc: PMC7073028
pii:
doi:
Substances chimiques
Circulating MicroRNA
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG20774
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : MFAG14361
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 16900
Références
Cell Death Dis. 2017 Sep 7;8(9):e3045
pubmed: 28880270
Oncotarget. 2016 Sep 27;7(39):64431-64446
pubmed: 26824988
Breast Cancer Res Treat. 2014 Aug;147(1):61-8
pubmed: 25086636
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
J Mol Cell Biol. 2013 Feb;5(1):3-13
pubmed: 22935141
J Clin Oncol. 2014 Oct 10;32(29):3212-20
pubmed: 25199759
Anal Biochem. 2014 Sep 15;461:7-9
pubmed: 24892985
Clin Cancer Res. 2015 Feb 1;21(3):569-76
pubmed: 25467182
Clin Epigenetics. 2018 Apr 23;10:59
pubmed: 29713393
J Oncol. 2013;2013:854121
pubmed: 23737784
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
Mol Cancer Res. 2019 Jun;17(6):1403-1413
pubmed: 30872332
Mol Cancer Ther. 2015 Nov;14(11):2642-52
pubmed: 26310543
Cancer. 2012 May 15;118(10):2603-14
pubmed: 22370716
J Cell Physiol. 2002 Dec;193(3):287-92
pubmed: 12384981
Clin Cancer Res. 2014 Dec 15;20(24):6247-53
pubmed: 25512634
PLoS One. 2011;6(6):e20980
pubmed: 21738599
World J Surg Oncol. 2018 Aug 22;16(1):174
pubmed: 30134903
Cancer Res. 2009 Sep 15;69(18):7270-7
pubmed: 19738069
Cancer Res. 2005 Nov 15;65(22):10585-93
pubmed: 16288052
PLoS One. 2018 Oct 18;13(10):e0206239
pubmed: 30335862
Oncogene. 2015 Oct;34(43):5482-93
pubmed: 25703326
J Cancer. 2016 Jun 21;7(10):1233-41
pubmed: 27390598
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
J Cell Mol Med. 2019 May;23(5):3063-3076
pubmed: 30772950
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424
pubmed: 30796368
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Oncotarget. 2016 Apr 12;7(15):20381-94
pubmed: 26967387
Clin Cancer Res. 2019 Jul 1;25(13):3887-3895
pubmed: 30814109
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
ScientificWorldJournal. 2014;2014:565839
pubmed: 25114970
Biochem Biophys Res Commun. 2014 Aug 15;451(1):74-8
pubmed: 25063027
J Biomed Res. 2011 May;25(3):170-7
pubmed: 23554686
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Sci Rep. 2016 Sep 21;6:33825
pubmed: 27650797